Human Pluripotent Stem Cell Therapy for Huntington's Disease: Technical, Immunological, and Safety Challenges

Neurotherapeutics

Volumn 8, Issue 4, 2011, Pages 562-576

  Nicoleau, Camille ^a   Viegas, Pedro ^a   Peschanski, Marc ^a   Perrier, Anselme L ^a  

^a I Stem   (France)

Author keywords

Cell therapy; Embryonic stem cells; Huntington's disease; Induced pluripotent stem cells; Neural stem cells; Pluripotent stem cells; Transplantation

Indexed keywords

COGNITION; FETUS CELL; HUMAN; HUNTINGTON CHOREA; IMMUNOGENICITY; NERVE CELL; NERVE GRAFT; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; STEM CELL TRANSPLANTATION;

HUMANS; HUNTINGTON DISEASE; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 80955143534     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0079-4     Document Type: Review

References (136)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Peschanski M, Cesaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995; 68: 273-285.
3. Palfi S, Conde F, Riche D, et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 1998; 4: 963-966.
4. Kendall AL, Rayment FD, Torres EM, Baker HF, Ridley RM, Dunnett SB. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998; 4: 727-729.
5. Bachoud-Levi A, Bourdet C, Brugieres P, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000; 161: 194-202.
6. Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000; 356: 1975-1979.
7. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002; 58: 687-695.
8. Rosser AE, Barker RA, Harrower T, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002; 73: 678-685.
9. Keene CD, Sonnen JA, Swanson PD, et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007; 68: 2093-2098.
10. Reuter I, Tai YF, Pavese N, et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry 2008; 79: 948-951.
11. Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006; 5: 303-309.
12. Dunnett SB, Rosser AE. Stem cell transplantation for Huntington's disease. Exp Neurol 2007; 203: 279-292.
13. Thomson JA. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
14. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
15. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
16. Grasbon-Frodl EM, Nakao N, Lindvall O, Brundin P. Phenotypic development of the human embryonic striatal primordium: a study of cultured and grafted neurons from the lateral and medial ganglionic eminences. Neuroscience 1996; 73: 171-183.
17. Naimi S, Jeny R, Hantraye P, Peschanski M, Riche D. Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult rat brain. Exp Neurol 1996; 137: 15-25.
18. Wictorin K. Anatomy and connectivity of intrastriatal striatal transplants. Prog Neurobiol 1992; 38: 611-639.
19. Dunnett SB. Functional analysis of fronto-striatal reconstruction by striatal grafts. Novartis Found Symp 2000; 231: 21-52.
20. Dunnett SB, Meldrum A, Muir JL. Frontal-striatal disconnection disrupts cognitive performance of the frontal-type in the rat. Neuroscience 2005; 135: 1055-1065.
21. Freeman TB, Hauser RA, Willing AE, Zigova T, Sanberg PR, Saporta S. Transplantation of human fetal striatal tissue in Huntington's disease: rationale for clinical studies. Novartis Found Symp 2000; 231: 129-47.
22. Cicchetti F, Saporta S, Hauser RA, et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci USA 2009; 106: 12483-12488.
23. Eriksson C, Bjorklund A, Wictorin K. Neuronal differentiation following transplantation of expanded mouse neurosphere cultures derived from different embryonic forebrain regions. Exp Neurol 2003; 184: 615-635.
24. Fricker-Gates RA, Winkler C, Kirik D, Rosenblad C, Carpenter MK, Bjorklund A. EGF infusion stimulates the proliferation and migration of embryonic progenitor cells transplanted in the adult rat striatum. Exp Neurol 2000; 165: 237-247.
25. Svendsen CN, Clarke DJ, Rosser AE, Dunnett SB. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp Neurol 1996; 137: 376-388.
26. Visnyei K, Tatsukawa KJ, Erickson RI, et al. Neural progenitor implantation restores metabolic deficits in the brain following striatal quinolinic acid lesion. Exp Neurol 2006; 197: 465-474.
27. Mukhida K, Mendez I, McLeod M, et al. Spinal GABAergic transplants attenuate mechanical allodynia in a rat model of neuropathic pain. Stem Cells 2007; 25: 2874-2885.
28. Armstrong RJ, Watts C, Svendsen CN, Dunnett SB, Rosser AE. Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease. Cell Transplant 2000; 9: 55-64.
29. El Akabawy G, Martinez-Medina L, Jeffries AR, Price J, Modo M. Purmorphamine increases DARPP-32 differentiation in human striatal neural stem cells through the hedgehog pathway. Stem Cells Dev [serial online] 2011; Available at: www.liebertonline.com/scd. Accessed September 15, 2011.
30. Mizuseki K, Kishi M, Matsui M, Nakanishi S, Sasai Y. Xenopus Zic-related-1 and Sox-2, two factors induced by chordin, have distinct activities in the initiation of neural induction. Development 1998; 125: 579-587.
31. Rex M, Orme A, Uwanogho D, et al. Dynamic expression of chicken Sox2 and Sox3 genes in ectoderm induced to form neural tissue. Dev Dyn 1997; 209: 323-332.
32. Sheng G, dos Reis M, Stern CD. Churchill, a zinc finger transcriptional activator, regulates the transition between gastrulation and neurulation. Cell 2003; 115: 603-613.
33. Zhang X, Huang CT, Chen J, et al. Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell 2010; 7: 90-100.
34. Tao W, Lai E. Telencephalon-restricted expression of BF-1, a new member of the HNF-3/fork head gene family, in the developing rat brain. Neuron 1992; 8: 957-966.
35. Shimamura K, Rubenstein JL. Inductive interactions direct early regionalization of the mouse forebrain. Development 1997; 124: 2709-2718.
36. Muzio L, Mallamaci A. Emx1, emx2 and pax6 in specification, regionalization and arealization of the cerebral cortex. Cereb Cortex 2003; 13: 641-647.
37. Anderson SA, Qiu M, Bulfone A, et al. Mutations of the homeobox genes Dlx-1 and Dlx-2 disrupt the striatal subventricular zone and differentiation of late born striatal neurons. Neuron 1997; 19: 27-37.
38. Corbin JG, Gaiano N, Machold RP, Langston A, Fishell G. The Gsh2 homeodomain gene controls multiple aspects of telencephalic development. Development 2000; 127: 5007-5020.
39. Toresson H, Parmar M, Campbell K. Expression of Meis and Pbx genes and their protein products in the developing telencephalon: implications for regional differentiation. Mech Dev 2000; 94: 183-187.
40. Szucsik JC, Witte DP, Li H, Pixley SK, Small KM, Potter SS. Altered forebrain and hindbrain development in mice mutant for the Gsh-2 homeobox gene. Dev Biol 1997; 191: 230-242.
41. Jain M, Armstrong RJ, Barker RA, Rosser AE. Cellular and molecular aspects of striatal development. Brain Res Bull 2001; 55: 533-540.
42. Deacon TW, Pakzaban P, Isacson O. The lateral ganglionic eminence is the origin of cells committed to striatal phenotypes: neural transplantation and developmental evidence. Brain Res 1994; 668: 211-219.
43. Campbell K, Olsson M, Bjorklund A. Regional incorporation and site-specific differentiation of striatal precursors transplanted to the embryonic forebrain ventricle. Neuron 1995; 15: 1259-1273.
44. Walaas SI, Greengard P. DARPP-32, a dopamine- and adenosine 3': 5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J Neurosci 1984; 4: 84-98.
45. Ouimet CC, Greengard P. Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J Neurocytol 1990; 19: 39-52.
46. Arlotta P, Molyneaux BJ, Jabaudon D, Yoshida Y, Macklis JD. Ctip2 controls the differentiation of medium spiny neurons and the establishment of the cellular architecture of the striatum. J Neurosci 2008; 28: 622-632.
47. Ferland RJ, Cherry TJ, Preware PO, Morrisey EE, Walsh CA. Characterization of Foxp2 and Foxp1 mRNA and protein in the developing and mature brain. J Comp Neurol 2003; 460: 266-279.
48. Tamura S, Morikawa Y, Iwanishi H, Hisaoka T, Senba E. Foxp1 gene expression in projection neurons of the mouse striatum. Neuroscience 2004; 124: 261-267.
49. Rakic P. Evolution of the neocortex: a perspective from developmental biology. Nat Rev Neurosci 2009; 10: 724-735.
50. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001; 19: 1129-1133.
51. Carpenter MK, Inokuma MS, Denham J, Mujtaba T, Chiu CP, Rao MS. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol 2001; 172: 383-397.
52. Reubinoff BE, Itsykson P, Turetsky T, et al. Neural progenitors from human embryonic stem cells. Nat Biotechnol 2001; 19: 1134-1140.
53. Rathjen J, Rathjen PD. Formation of neural precursor cell populations by differentiation of embryonic stem cells in vitro. ScientificWorldJournal 2002; 2: 690-700.
54. Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004; 101: 12543-12548.
55. Kawasaki H, Mizuseki K, Sasai Y. Selective neural induction from ES cells by stromal cell-derived inducing activity and its potential therapeutic application in Parkinson's disease. Methods Mol Biol 2002; 185: 217-227.
56. Kawasaki H, Suemori H, Mizuseki K, et al. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc Natl Acad Sci USA 2002; 99: 1580-1585.
57. Cibelli JB, Grant KA, Chapman KB, et al. Parthenogenetic stem cells in nonhuman primates. Science 2002; 295: 819.
58. Ying QL, Stavridis M, Griffiths D, Li M, Smith A. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol 2003; 21: 183-186.
59. Lee H, Al Shamy G, Elkabetz Y, et al. Directed Differentiation And Transplantation of Human Embryonic Stem Cell Derived Motoneurons. Stem Cells 2007; 25: 1931-1939.
60. Sonntag KC, Pruszak J, Yoshizaki T, van Arensbergen J, Sanchez-Pernaute R, Isacson O. Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 2007; 25: 411-418.
61. Elkabetz Y, Panagiotakos G, Al Shamy G, Socci ND, Tabar V, Studer L. Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev 2008; 22: 152-165.
62. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27: 275-280.
63. Benchoua A, Aubry L, Perrier A, et al. Method and medium for neural differentiation of pluripotent cells. 2008; 10. 06. 2010.
64. Dinsmore J, Ratliff J, Deacon T, et al. Embryonic stem cells differentiated in vitro as a novel source of cells for transplantation. Cell Transplant 1996; 5: 131-143.
65. Watanabe K, Kamiya D, Nishiyama A, et al. Directed differentiation of telencephalic precursors from embryonic stem cells. Nat Neurosci 2005; 8: 288-296.
66. Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 2007; 25: 681-686.
67. Danjo T, Eiraku M, Muguruma K, et al. Subregional specification of embryonic stem cell-derived ventral telencephalic tissues by timed and combinatory treatment with extrinsic signals. J Neurosci 2011; 31: 1919-1933.
68. Song J, Lee ST, Kang W, et al. Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions. Neurosci Lett 2007; 423: 58-61.
69. Ferrari D, Sanchez-Pernaute R, Lee H, Studer L, Isacson O. Transplanted dopamine neurons derived from primate ES cells preferentially innervate DARPP-32 striatal progenitors within the graft. Eur J Neurosci 2006; 24: 1885-1896.
70. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci USA 2008; 105: 16707-16712.
71. Li XJ, Zhang X, Johnson MA, Wang ZB, Lavaute T, Zhang SC. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. Development 2009; 136: 4055-4063.
72. Nasonkin I, Mahairaki V, Xu L, et al. Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. Stem Cells 2009; 27: 2414-2426.
73. Freeman TB, Cicchetti F, Bachoud-Levi AC, Dunnett SB. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol 2011; 227: 1-9.
74. Olsson M, Campbell K, Wictorin K, Bjorklund A. Projection neurons in fetal striatal transplants are predominantly derived from the lateral ganglionic eminence. Neuroscience 1995; 69: 1169-1182.
75. Pakzaban P, Deacon TW, Burns LH, Isacson O. Increased proportion of acetylcholinesterase-rich zones and improved morphological integration in host striatum of fetal grafts derived from the lateral but not the medial ganglionic eminence. Exp Brain Res 1993; 97: 13-22.
76. Freeman TB, Cicchetti F, Hauser RA, et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci USA 2000; 97: 13877-13882.
77. Grasbon-Frodl EM, Nakao N, Lindvall O, Brundin P. Developmental features of human striatal tissue transplanted in a rat model of Huntington's disease. Neurobiol Dis 1997; 3: 299-311.
78. Mamelak AN, Eggerding FA, Oh DS, et al. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. J Neurosurg 1998; 89: 592-598.
79. Freeman TB, Hauser RA, Sanberg PR. Fatal transplant cyst. J Neurosurg 1999; 90: 1148-1150.
80. Folkerth RD, Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 1996; 46: 1219-1225.
81. Watts C, Brasted PJ, Dunnett SB. Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease. Exp Neurol 2000; 163: 85-97.
82. Brundin P, Widner H, Nilsson OG, Strecker RE, Bjorklund A. Intracerebral xenografts of dopamine neurons: the role of immunosuppression and the blood-brain barrier. Exp Brain Res 1989; 75: 195-207.
83. Rosenstein JM. Neocortical transplants in the mammalian brain lack a blood-brain barrier to macromolecules. Science 1987; 235: 772-774.
84. Crook JM, Peura TT, Kravets L, et al. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 2007; 1: 490-494.
85. Li Y, Powell S, Brunette E, Lebkowski J, Mandalam R. Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. Biotechnol Bioeng 2005; 91: 688-698.
86. Tecirlioglu RT, Nguyen L, Koh K, Trounson AO, Michalska AE. Derivation and maintenance of human embryonic stem cell line on human adult skin fibroblast feeder cells in serum replacement medium. In Vitro Cell Dev Biol Anim 46: 231-235.
87. Richards M, Fong CY, Chan WK, Wong PC, Bongso A. Human feeders support prolonged undifferentiated growth of human inner cell masses and embryonic stem cells. Nat Biotechnol 2002; 20: 933-936.
88. Sidhu KS, Lie KH, Tuch BE. Transgenic human fetal fibroblasts as feeder layer for human embryonic stem cell lineage selection. Stem Cells Dev 2006; 15: 741-747.
89. Stacey GN, Cobo F, Nieto A, Talavera P, Healy L, Concha A. The development of 'feeder' cells for the preparation of clinical grade hES cell lines: challenges and solutions. J Biotechnol 2006; 125: 583-588.
90. Tsutsui H, Valamehr B, Hindoyan A, et al. An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nat Commun [serial online] 2010; 2: 167. Available at: www.nature.com/ncomms. Accessed September 15, 2011.
91. Klimanskaya I, Chung Y, Meisner L, Johnson J, West MD, Lanza R. Human embryonic stem cells derived without feeder cells. Lancet 2005; 365: 1636-1641.
92. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008; 322: 945-949.
93. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4: 381-384.
94. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-953.
95. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-476.
96. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7: 618-630.
97. Barker RA, Widner H. Immune problems in central nervous system cell therapy. NeuroRx 2004; 1: 472-481.
98. Silvestroni A, Faull RL, Strand AD, Moller T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 2009; 20: 1098-1103.
99. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-180.
100. Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). N Engl J Med 1992; 327: 1556-1563.
101. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
102. Defer GL, Geny C, Ricolfi F, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996; 119(pt 1): 41-50.
103. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-414.
104. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38: 379-388.
105. Capetian P, Knoth R, Maciaczyk J, et al. Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation. Neuroscience 2009; 160: 661-675 d.
106. Gallina P, Paganini M, Di Rita A, et al. Human fetal striatal transplantation in huntington's disease: a refinement of the stereotactic procedure. Stereotact Funct Neurosurg 2008; 86: 308-313.
107. Krystkowiak P, Gaura V, Labalette M, et al. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS ONE 2007; 2: e166.
108. Tai YF, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130: 1759-1766.
109. Pavese N, Politis M, Tai YF, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 37: 356-361.
110. Brundin P, Bjorklund A, Lindvall O. Practical aspects of the use of human fetal brain tissue for intracerebral grafting. Prog Brain Res 1990; 82: 707-714.
111. Kordower JH, Goetz CG, Freeman TB, Olanow CW. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol 1997; 144: 41-46.
112. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
113. Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005; 11: 228-232.
114. Chung TL, Turner JP, Thaker NY, et al. Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells. Stem Cells 2010; 28: 1782-1793.
115. Prowse AB, Doran MR, Cooper-White JJ, et al. Long term culture of human embryonic stem cells on recombinant vitronectin in ascorbate free media. Biomaterials 2010; 31: 8281-8288.
116. Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 2004; 22: 53-54.
117. Lefort N, Feyeux M, Bas C, et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11. 21. Nat Biotechnol 2008; 26: 1364-1366.
118. Spits C, Mateizel I, Geens M, et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol 2008; 26: 1361-1363.
119. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467: 285-290.
120. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506.
121. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503.
122. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 2005; 366: 2019-2025.
123. Preynat-Seauve O, de Rham C, Tirefort D, Ferrari-Lacraz S, Krause KH, Villard J. Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. J Cell Mol Med 2009; 13: 3556-3569.
124. Brundin P, Karlsson J, Emgard M, et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 2000; 9: 179-195.
125. Kordower JH, Rosenstein JM, Collier TJ, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996; 370: 203-230.
126. Gallina P, Paganini M, Lombardini L, et al. Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol 2010; 222: 30-41.
127. Nauert GM, Freeman TB. Low-pressure aspiration abortion for obtaining embryonic and early gestational fetal tissue for research purposes. Cell Transplant 1994; 3: 147-151.
128. Keene CD, Chang RC, Leverenz JB, et al. A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol 2009; 117: 329-338.
129. Seminatore C, Polentes J, Ellman D, et al. The postischemic environment differentially impacts teratoma or tumor formation after transplantation of human embryonic stem cell-derived neural progenitors. Stroke 2010; 41: 153-159.
130. Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990; 1: 125-134.
131. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998; 9: 2595-2604.
132. Werbowetski-Ogilvie TE, Bosse M, Stewart M, et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol 2009; 27: 91-97.
133. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8: 106-118.
134. Sareen D, McMillan E, Ebert AD, et al. Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoS One 2009; 4: e7630.
135. Wu W, He Q, Li X, et al. Long-term Cultured Human Neural Stem Cells Undergo Spontaneous Transformation to Tumor-Initiating Cells. Int J Biol Sci 2011; 7: 892-901.
136. Zhao Y, Sheng HZ, Amini R, et al. Control of hippocampal morphogenesis and neuronal differentiation by the LIM homeobox gene Lhx5. Science 1999; 284: 1155-1158.